Intrinsic cancer subtypes-next steps into personalized medicine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Intrinsic cancer subtypes-next steps into personalized medicine

Published:2015-01-14 Issue:1 Volume:38 Page:3-16
ISSN:2211-3428
Container-title:Cellular Oncology
language:en
Short-container-title:Cell Oncol.

Author:

Santos Cristina,Sanz-Pamplona Rebeca,Nadal Ernest,Grasselli Julieta,Pernas Sonia,Dienstmann Rodrigo,Moreno Victor,Tabernero Josep,Salazar Ramon

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13402-014-0203-7.pdf

Reference106 articles.

1. A. Jemal et al., Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011)

2. I. Nishisho et al., Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253(5020), 665–669 (1991)

3. W. Eiermann, Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann. Oncol. 12(Suppl 1), S57–S62 (2001)

4. A. Goldhirsch, et al., 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897), 1021–1028

5. S.M. Swain et al., Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14(6), 461–471 (2013)

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticancer Activity of Benzo[a]phenoxazine Compounds Promoting Lysosomal Dysfunction;Cells;2024-08-20

2. In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer;RSC Medicinal Chemistry;2024

3. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy;British Journal of Cancer;2023-11-27

4. Explainable domain transfer of distant supervised cancer subtyping model via imaging-based rules extraction;Artificial Intelligence in Medicine;2023-04

5. Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer;Frontiers in Immunology;2021-12-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3